{"id":"W4312462526","doi":"10.1136/ijgc-2022-esgo.538","title":"2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bevacizumab; Pembrolizumab; Clinical endpoint; Ovarian cancer; Internal medicine; Response Evaluation Criteria in Solid Tumors; Placebo; Oncology; Progression-free survival; Paclitaxel; Phases of clinical research; Cancer; Surgery; Clinical trial; Chemotherapy; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001819584,0.002166481,0.002869182,0.0007342964,0.0005261653,0.001357891,0.001526788,0.002073985,0.01415789],"category_scores_gemma":[0.001123718,0.001046015,0.001716556,0.0004737976,0.001441342,0.001452462,0.0004398132,0.004908069,0.003011517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008626936,"about_ca_system_score_gemma":0.001641239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001832778,"about_ca_topic_score_gemma":0.004078304,"domain_scores_codex":[0.99958,0.0001805412,0.00002117789,0.00007894216,0.00003661131,0.0001027507],"domain_scores_gemma":[0.9994746,0.0001038752,0.00008268852,0.00004050777,0.00003075046,0.0002675822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9503663,0.01436927,0.0002919578,0.0007207496,0.000836759,0.00003469229,0.00005874215,0.000492999,0.007248994,0.0002782715,0.002118167,0.02318302],"study_design_scores_gemma":[0.9508246,0.04689685,0.000569828,0.00001809585,0.0001708716,0.00001770703,0.00001379754,0.0003049802,0.0004190532,0.00008702352,0.0006650554,0.00001220993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9684716,0.00606169,0.00194165,0.001341467,0.001285746,0.008797869,0.003586617,0.0009195272,0.007593761],"genre_scores_gemma":[0.966416,0.003913258,0.003505274,0.002164685,0.0006441509,0.007269943,0.002666349,0.0001458734,0.01327462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01415789,"threshold_uncertainty_score":0.04736286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07586500025897046,"score_gpt":0.3986865803564197,"score_spread":0.3228215800974493,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}